← All trials
NCT03287076
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2017
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 528
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Neuroscience Trials AustraliaLead sponsor
- National Health and Medical Research Council, AustraliaCollaborator
- Monash UniversityCollaborator
- The Florey Institute of Neuroscience & Mental Health Melbourne Brain CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.